MRVI240816C7500
- 1.70
- +0.30+21.43%
Maravai LifeSciences Newsroom
Maravai LifeSciences Analyst Ratings
RBC Capital Maintains Maravai LifeSciences(MRVI.US) With Buy Rating, Maintains Target Price $15
Morgan Stanley Downgrades Maravai LifeSciences(MRVI.US) to Hold Rating, Cuts Target Price to $10
Maravai LifeSciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Artiva Biotherapeutics, Inc. (ARTV), BioMarin Pharmaceutical (BMRN) and Maravai Lifesciences Holdings (MRVI)
Maravai Lifesciences: Hold Rating Amidst Mixed Performance and Revised EBITDA Margin Guidance
Maravai LifeSciences Price Target Raised to $11.00/Share From $8.50 by UBS
Buy Rating Affirmed for Maravai Lifesciences Amid Strong Growth Prospects and Operational Investments
Craig-Hallum Maintains Maravai LifeSciences(MRVI.US) With Buy Rating
Craig-Hallum Maintains Maravai LifeSciences(MRVI.US) With Buy Rating
Maravai LifeSciences Analyst Ratings
Maravai LifeSciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT), Arcus Biosciences (RCUS) and Maravai Lifesciences Holdings (MRVI)
Craig-Hallum Keeps Their Buy Rating on Maravai Lifesciences Holdings (MRVI)
Analysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (DMAC), Inspire Medical Systems (INSP) and Maravai Lifesciences Holdings (MRVI)
Maravai LifeSciences Analyst Ratings
RBC Capital Sticks to Its Buy Rating for Maravai Lifesciences Holdings (MRVI)
RBC Raises Price Target on Maravai LifeSciences Holdings to $15 From $14, Keeps Outperform Rating
Analysts Offer Insights on Healthcare Companies: Maravai Lifesciences Holdings (MRVI) and R1 RCM (RCM)
Buy Rating Affirmed for Maravai Lifesciences Amid Strong Financial Performance and Growth Outlook